Liposomal Vitamin B12 Pharma Grade API intended for immediate-release tablets is processed by direct compression only after a controlled dry pre-blend step, because the phospholipid bilayer is sensitive to both shear and moisture. The API powder is first passed through a 500 µm stainless-steel mesh on a vibratory sieve to break soft agglomerates without opening the liposomal carrier. Compaction is performed on a rotary tablet press with 8–12 stations and B-tooling, with main compression force mapped in the range of 5–15 kN. Outside this band two distinct failure modes appear: below 5 kN the compact lacks sufficient tensile strength and fails friability testing under USP <1216>; above 15 kN the lipid bilayers may undergo irreversible collapse, causing free cyanocobalamin or methylcobalamin to be released during dissolution rather than remaining associated with the liposomal fraction. Tablet breaking force is monitored by USP <1217> and is typically held between 40 N and 80 N for an 8 mm flat-faced bevel-edge tablet. Ejection force is logged as a process indicator; sustained ejection values above 800 N frequently correlate with phospholipid transfer to the die wall and should trigger cleaning or lubrication adjustment.

The pre-blend for direct compression uses a low-shear tumble blender operated at 10–15 rpm for 12–20 min, with 0.5–1.0 wt% magnesium stearate added during the final 3–5 min to limit over-lubrication. Because the Vitamin B12 active moiety is dosed at microgram levels, the liposomal carrier dominates the blend mass and requires a compressible diluent such as microcrystalline cellulose or mannitol-based co-processed filler. Particle size of the spray-dried or lyophilized liposomal B12 powder should be controlled with a D50 between 20 µm and 100 µm for acceptable flow; finer material elevates the Carr index above 30 and causes weight variation under USP <905>. The process environment is maintained at 20–25 °C and relative humidity below 35%, because partially hydrated phospholipid bilayers undergo a phase transition near human body temperature, producing surface tack and punch filming. Tablets are tested for dissolution using USP <711> apparatus 2 at 50–75 rpm in 900 mL of 0.1 N hydrochloric acid; release is monitored at 30 min and is acceptable only when the liposomal integrity marker and free Vitamin B12 are quantified separately by HPLC or ultracentrifugation. Amine-containing excipients are avoided because they can raise the microenvironmental pH and accelerate phospholipid hydrolysis.

What Limits Encapsulation Speed When Liposomal B12 Powder Is Dosed into HPMC Capsules?

Encapsulation of liposomal B12 powder into hard capsules is constrained by the low bulk density and cohesive nature of phospholipid-containing powders. On a dosator-type capsule filler, compression of the powder into the dosing tube can rupture the liposomal bilayer, while on a tamping-pin machine the repeated pin strokes densify the powder and raise the measured bulk density from a typical 0.25–0.45 g/mL to values above 0.55 g/mL, which is associated with reduced drug release at the 30-min USP <711> withdrawal. Tamping pin displacement is therefore limited to 0.2–0.5 mm per stroke, and the number of tamping stations is kept below the full set to avoid over-compaction. High-speed encapsulation above 20,000 capsules/h is generally avoided unless the API powder is pre-granulated into dense, free-flowing granules; published data for the direct encapsulation of unmodified liposomal B12 powder at speeds above this threshold is limited.

Capsule shell selection influences moisture transfer. HPMC shells contain 3–7% moisture and are preferred over gelatin shells with 13–16% moisture when the liposomal B12 powder has a water activity below 0.35. If the shell moisture migrates into the powder, localized hydration can initiate phospholipid hydrolysis and Vitamin B12 degradation. For stability, filled capsules are packed in HDPE bottles with a desiccant canister; a 1 g silica gel canister per 30-count bottle is commonly used, but the exact desiccant load is verified by moisture mapping at 40 °C/75% RH. Fill weight variation is controlled under USP <905> with an acceptance value not more than 15. Dissolution profiling is performed in 900 mL of pH 1.2 or pH 4.5 media, and the capsule shell itself can delay rupture by 2–4 min depending on shell viscosity grade; this lag is recorded in the dissolution profile and not attributed to the API.

Granule-based oral formats require a physical carrier, usually sucrose spheres or mannitol-based cores, because the microgram-level Vitamin B12 content cannot sustain a sachet fill weight by itself. Liposomal Vitamin B12 API is dispersed in an aqueous binder solution prepared at 4–8 °C to keep the phospholipid bilayer below its phase transition during the spraying step. Hypromellose or povidone serves as the binder at 2–5% w/w of dry granule mass. Fluid-bed top-spray granulation is operated with inlet air temperature between 45 °C and 55 °C, product temperature between 28 °C and 32 °C, atomizing air pressure from 1.5 bar to 2.2 bar, and a spray rate of 8–15 g/min for a 3 kg pilot-scale batch. Loss on drying after the drying phase is controlled by USP <731> and targeted at ≤3.0% w/w, because residual moisture above this level softens the liposomal matrix and lowers the glass transition of the carrier.

The granule fraction is sieved through 20–40 mesh screens, and any oversized fraction is dry-milled with low shear to avoid exposing the liposomal carrier to mechanical stress. High-shear granulation is generally avoided because the mechanical energy input can raise product temperature above 35 °C and rupture the bilayer; if high-shear equipment is used, the jacket temperature is set to 10–15 °C and impeller speed is maintained below 200 rpm. Colloidal silicon dioxide or talc at 0.5–1.0% is added as a glidant to reduce interparticle friction during sachet filling on auger or volumetric fillers. Fill weight variation in stick-pack or sachet lines is monitored gravimetrically every 15–30 min; the target fill weight is set so that each sachet contains the labelled Vitamin B12 dose with a variability below ±5%. Reconstitution of the granule in water at 25 °C should produce a dispersion with a D50 particle size measured by dynamic light scattering using ISO 22412:2017 that does not exceed the original liposome size by more than 20%, indicating that the granulation and drying steps have not caused liposomal fusion. If the granule is formulated as an effervescent or dispersible powder, acid-base effervescent couples are segregated from the liposomal component until final dry blending to prevent localized low-pH degradation. Stick-pack laminate structures are specified with an oxygen transmission rate below 0.1 cm³/(m²·day) at 25 °C/60% RH and an aluminium foil barrier to limit oxidative degradation of Vitamin B12.

Lyophilization Cycle Design for Liposomal Vitamin B12 Injection Requires a Collapse-Temperature Buffer

The lyophilization of liposomal Vitamin B12 for injectable presentation is governed by the interplay between the phospholipid phase transition and the collapse temperature of the cryoprotectant matrix. The sterile-filtered liposomal dispersion, typically with a D50 below 200 nm, is filled into Type I borosilicate vials and freeze-dried in a lyophilizer equipped with controlled shelf-temperature ramping. A cryoprotectant such as trehalose or sucrose is required at 5–10% w/v; mannitol is used only as a bulking agent because its crystalline nature can damage the bilayer during freezing. The collapse temperature is determined by freeze-dry microscopy, and primary drying shelf temperature is set 2–5 °C below that value to prevent cake collapse. A controlled annealing step at -20 °C to -15 °C for 2–4 h is introduced when mannitol is present to allow complete crystallization of the bulking agent and reduce vial breakage. For a fill volume of 1–2 mL in a 5 mL vial, cake height is kept below 5 mm to avoid excessive mass-transfer resistance during primary drying.

Residual moisture in the lyophilized cake is measured by Karl Fischer titration according to USP <921> Method Ia and is maintained at ≤3.0% w/w. Higher residual moisture accelerates hydrolysis of unsaturated phospholipids and shortens the shelf life of Vitamin B12 in the cake. After reconstitution with sterile water for injection, the resulting dispersion must meet USP <788> subvisible particulate limits: for small-volume injections, not more than 6000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm. Osmolality of the reconstituted injection is adjusted with sodium chloride or glucose and tested by USP <785> to a target of 270–320 mOsm/kg. Liposome size after reconstitution is confirmed by DLS using ISO 22412:2017, and the polydispersity index is maintained below 0.25 to avoid a broad population that could cause variable pharmacokinetics. Sterilizing-grade filtration is performed through a 0.2 µm polyethersulfone membrane; filtration pressure is kept below 0.5 bar to reduce shear-induced liposome rupture. The entire filling and lyophilization operation is performed in a Grade A aseptic environment under EU GMP Annex 1 and FDA 21 CFR 211.113. If the liposome D50 exceeds 200 nm, sterile filtration is not feasible and aseptic processing without terminal filtration is required.

When Liposomal Vitamin B12 Is Dispersed in Low-pH Oral Vehicles, Bilayer Hydrolysis and Payload Leakage Accelerate

In aqueous oral vehicles buffered below pH 5.0, the hydrolytic degradation of phosphatidylcholine accelerates, and the liposomal bilayer may lose its ability to retain Vitamin B12. Oral liquid and oral drop formulations therefore use a citrate or phosphate buffer to hold pH between 5.5 and 6.5. Zeta potential is measured by electrophoretic light scattering according to ISO 13099-1:2012; a value more negative than -30 mV is generally required for electrostatic stabilization, and a fall to -10 mV or less indicates that aggregation is likely. The preservative system is selected for low bilayer partitioning: benzyl alcohol at 0.5–1.0% w/v or sodium benzoate at 0.1–0.2% w/v may be used, but higher concentrations can fluidize the bilayer and increase free Vitamin B12 leakage during storage.

High-shear mixing is avoided; a propeller or magnetic stirrer operating at 200–400 rpm is sufficient to disperse the liposomal B12 concentrate into the buffered vehicle. The finished oral liquid is stored in amber Type III glass or polyethylene terephthalate containers because Vitamin B12 is photolabile and undergoes accelerated degradation under visible light. Degradation products are monitored by HPLC using the USP Cyanocobalamin monograph, and the total impurities at release are controlled below the monograph limits. Shelf-life stability is evaluated at 25 °C/60% RH, 30 °C/65% RH, and 40 °C/75% RH; the 40 °C condition frequently identifies free Vitamin B12 leakage that is not visible by particle sizing, so encapsulation efficiency is measured at each withdrawal interval. In oral vehicles containing metal ions such as iron or copper, the addition of a chelating agent is required because trace metals catalyze lipid peroxidation and Vitamin B12 degradation; EDTA is used at 0.005–0.01% w/v in such formulations. Published data for long-term liposomal integrity in all possible preservative and buffer combinations remains limited, so each formulation requires stress testing under the intended storage orientation and container-closure system.